These data provide potential mechanisms which explain that IL–20 not only triggers the entrance of prostate tumor cells into the bone microenvironment, but also increases prostate cancer-induced osteolysis by regulating the RANKL-RANK pathway and modulating osteoclastogenesis. Here, IL20 is linked to prostate cancer.